What is the recommendation for renin-angiotensin system inhibition with ACE inhibitors, ARBs, or ARNIs in patients with chronic HF with reduced ejection fraction?
The clinical strategy of inhibition of the renin-angiotensin system with ACE inhibitors (Level of Evidence: A), OR ARBs (Level of Evidence: A) OR ARNI (Level of Evidence: B-R) in conjunction with evidence-based beta blockers, and aldosterone antagonists in selected is recommended for patients with chronic HFrEF to reduce morbidity and mortality.